| Viral coagulopathy in patients with COVID-19: treatment and care N Kipshidze, G Dangas, CJ White, N Kipshidze, F Siddiqui, CR Lattimer, ... Clinical and Applied Thrombosis/Hemostasis 26, 1076029620936776, 2020 | 109 | 2020 |
| An update on the pathogenesis of COVID-19 and the reportedly rare thrombotic events following vaccination B Kantarcioglu, O Iqbal, JM Walenga, B Lewis, J Lewis, CA Carter, ... Clinical and Applied Thrombosis/Hemostasis 27, 10760296211021498, 2021 | 59 | 2021 |
| Reversal of factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values F Siddiqui, A Tafur, LS Ramacciotti, W Jeske, D Hoppensteadt, ... Clinical and Applied Thrombosis/Hemostasis 25, 1076029619863493, 2019 | 28 | 2019 |
| Upregulation of inflammatory cytokines in pulmonary embolism using biochip-array profiling E Bontekoe, Y Brailovsky, D Hoppensteadt, J Bontekoe, F Siddiqui, ... Clinical and Applied Thrombosis/Hemostasis 27, 10760296211013107, 2021 | 26 | 2021 |
| The COVID-19 pandemic and the need for an integrated and equitable approach: an international expert consensus paper GT Gerotziafas, M Catalano, Y Theodorou, P Van Dreden, V Marechal, ... Thrombosis and Haemostasis 121 (08), 992-1007, 2021 | 25 | 2021 |
| Factor Xa inhibitory profile of apixaban, betrixaban, edoxaban, and rivaroxaban does not fully reflect their biologic spectrum F Siddiqui, D Hoppensteadt, W Jeske, O Iqbal, A Tafur, J Fareed Clinical and Applied Thrombosis/Hemostasis 25, 1076029619847524, 2019 | 23 | 2019 |
| Bovine mucosal heparins are comparable to porcine mucosal heparin at USP potency adjusted levels W Jeske, A Kouta, A Farooqui, F Siddiqui, V Rangnekar, M Niverthi, ... Frontiers in medicine 5, 360, 2019 | 21 | 2019 |
| Is the reason of increased D-dimer levels in COVID-19 because of ACE-2-induced apoptosis in endothelium? N Guler, F Siddiqui, J Fareed Clinical and Applied Thrombosis/Hemostasis 26, 1076029620935526, 2020 | 19 | 2020 |
| Assay-based differentiation in the neutralization profile of unfractionated heparin, enoxaparin, and fondaparinux by andexanet alfa F Siddiqui, A Tafur, E Bontekoe, O Iqbal, W Jeske, S Mehrotra, ... Clinical and Applied Thrombosis/Hemostasis 26, 1076029619895120, 2020 | 17 | 2020 |
| The role of IL-13, IL-15 and granulysin in the pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis M Sadek, O Iqbal, F Siddiqui, S Till, M Mazariegos, E Campbell, ... Clinical and Applied Thrombosis/Hemostasis 27, 1076029620950831, 2021 | 12 | 2021 |
| Targeted, site-specific, delivery vehicles of therapeutics for COVID-19 patients. brief review N Kipshidze, P Iversen, TR Porter, N Kipshidze, F Siddiqui, G Dangas, ... Clinical and Applied Thrombosis/Hemostasis 26, 1076029620954911, 2020 | 11 | 2020 |
| Cellular indices and outcome in patients with acute venous thromboembolism F Siddiqui, A García-Ortega, B Kantarcioglu, J Sinacore, A Tafur, ... Clinical and Applied Thrombosis/Hemostasis 28, 10760296221113346, 2022 | 10 | 2022 |
| Comparative anticoagulant and thrombin generation inhibitory profile of heparin, sulodexide and its components F Siddiqui, D Hoppensteadt, E Bontekoe, A Farooqui, W Jeske, J Fareed Clinical and Applied Thrombosis/Hemostasis 26, 1076029620954913, 2020 | 10 | 2020 |
| Structural characterization of a clinically described heparin-like substance in plasma causing bleeding Y Yu, K Bruzdoski, V Kostousov, L Hensch, S Hui, F Siddiqui, A Farooqui, ... Carbohydrate polymers 244, 116443, 2020 | 7 | 2020 |
| Predictive role of blood cellular indices and their relationship with endogenous glycosaminoglycans as determinants of inflammatory biomarkers in pulmonary embolism B Kantarcioglu, A Darki, F Siddiqui, E Krupa, M Vural, M Kacmaz, ... Clinical and Applied Thrombosis/Hemostasis 28, 10760296221104801, 2022 | 6 | 2022 |
| Public perceptions of current COVID-19 vaccinations. results of a pilot survey B Kantarcioglu, K Patel, J Lewis, O Iqbal, F Siddiqui, N Jabeen, AR Laddu, ... Clinical and Applied Thrombosis/Hemostasis 27, 10760296211066942, 2021 | 6 | 2021 |
| Fibrinolytic status and risk of death after acute pulmonary embolism Y Brailovsky, V Lakhter, J Newman, S Allen, A Elkaryoni, P Desai, ... Clinical and Applied Thrombosis/Hemostasis 29, 10760296231162079, 2023 | 5 | 2023 |
| Glycemic control and plasma levels of pro-inflammatory and pro-thrombotic biomarkers in diabetic patients presenting with acute pulmonary embolism A O’Hara, J Pozin, A Darki, F Siddiqui, D Hoppensteadt, J Walenga, ... Clinical and Applied Thrombosis/Hemostasis 29, 10760296231165058, 2023 | 4 | 2023 |
| Collagen remodeling and fatty acid regulation biomarkers in understanding the molecular pathogenesis of atrial fibrillation A Odeh, GD Dungan, A Darki, D Hoppensteadt, F Siddiqui, B Kantarcioglu, ... Clinical and Applied Thrombosis/Hemostasis 28, 10760296221145181, 2022 | 4 | 2022 |
| The relevance of anti-PF4 antibody isotypes and endogenous glycosaminoglycans and their relationship with inflammatory biomarkers in pulmonary embolism patients B Kantarcioglu, A Darki, F Siddiqui, D Hoppensteadt, J Lewis, R Krämer, ... Clinical and Applied Thrombosis/Hemostasis 28, 10760296221091770, 2022 | 4 | 2022 |
Omer IqbalProfessor of Opthalmology & Pathology, Loyola University Stritch School of Medicine.在 luc.edu 的电子邮件经过验证
